Parsippany Chapter Upcoming Events Join PCCI

Monday, November 8, 2010

Embassy Suites, Chesterbrook, Pennsylvania (directions)

 

Plurogen Therapeutics

Skin care company

Presenter: Neal Koller, President & CEO of PluroGen

About

 

PluroGen is a burn, wound, and skin care company commercializing their multiple patent-protected technology platforms, the first of which is their core gel technology that provides superior and differentiated physical, bio-impact, and multi-function benefits. PluroGen's multiple technology platforms are configurable to deliver a wide variety of medicinal and beneficial compounds as protected and advanced therapeutic and topical products for simple and complex skin care and burn and wound healing. PluroGen's product pipeline targets improved , protected therapies for six areas of treatment in tissue management and healing: Cleansing, Anti-infection, Reduce pain, Reduce inflammation, Tissue salvage, and Tissue regeneration.

 

Initially, Plurogel(r) and Activigel(tm), are being used in skin and wound cleansing products, for personal skin care products, and two branded topical antimicrobial products: Plurogel(r) Barrier Gels and PluroGel(r) Barrier Dressings.

 

Plurogel(r)/Activigel(tm) technology is currently in routine use at the University of Virginia Medical Center, having shown superior results on more than 9,000 patients, in two different patient populations, severe burns and chronic wounds. The Plurogel management and operational teams, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen's target markets of burn and wound care and in the life sciences industry.

 

 

3 Major Issues

 

  1. Regulatory: Is PluroGen's triple antibiotic eligible for FDA's FastTrack, Accelerated Approval, or Priority Review and which is the best option in terms of speed to market?
  2. Clinical: Can a product that is intended to be used initially in the military (battlefield trauma) and eventually by the general public (everyday trauma), go through clinical trials only in military medical institutions or must civilians be involved in the trials?
  3. Financial: In today’s volatile financial environment, what is the best way for a company like Plurogen to plan its exit strategy? What exit strategy or strategies are viewed favorably by investors?

 

 

Program:

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Neal Koller, President & CEO of PluroGen, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests

 

 

<Top of the page>

 

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

None available at this time

Contact Info:

 

 

List of Attendees

 

 

 

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc